Common Contracts
7 similar Underwriting Agreement contracts by 7 Acquisition Corp, Ibere Pharmaceuticals, JATT Acquisition Corp
Underwriting AgreementUnderwriting Agreement • October 28th, 2021 • 7 Acquisition Corp • Blank checks • New York
Each Unit consists of one Class A ordinary share of the Company, par value U.S. $0.0001 per share (the “Ordinary Shares”), and one-third of one warrant, where each whole warrant entitles the holder to purchase one Ordinary Share (the “Warrant(s)”). The Ordinary Shares and Warrants included in the Units will not trade separately until the 52nd day following the date of the Prospectus (as defined below) (unless the Underwriter informs the Company of its decision to allow earlier separate trading), subject to (a) the Company’s preparation of an audited balance sheet reflecting the receipt by the Company of the proceeds of the Offering (as defined below), (b) the filing of such audited balance sheet with the Securities and Exchange Commission (the “Commission”) on a Current Report on Form 8-K or similar form by the Company that includes such audited balance sheet (the “Closing Form 8-K”), and (c) the Company having issued a press release announcing when such separate trading will begin. No
Underwriting AgreementUnderwriting Agreement • October 20th, 2021 • 7 Acquisition Corp • Blank checks • New York
Each Unit consists of one Class A ordinary share of the Company, par value U.S. $0.0001 per share (the “Ordinary Shares”), and one-half of one warrant, where each whole warrant entitles the holder to purchase one Ordinary Share (the “Warrant(s)”). The Ordinary Shares and Warrants included in the Units will not trade separately until the 52nd day following the date of the Prospectus (as defined below) (unless the Underwriter informs the Company of its decision to allow earlier separate trading), subject to (a) the Company’s preparation of an audited balance sheet reflecting the receipt by the Company of the proceeds of the Offering (as defined below), (b) the filing of such audited balance sheet with the Securities and Exchange Commission (the “Commission”) on a Current Report on Form 8-K or similar form by the Company that includes such audited balance sheet (the “Closing Form 8-K”), and (c) the Company having issued a press release announcing when such separate trading will begin. No
Underwriting AgreementUnderwriting Agreement • September 10th, 2021 • 7 Acquisition Corp • Blank checks • New York
Each Unit consists of one Class A ordinary share of the Company, par value U.S. $0.0001 per share (the “Ordinary Shares”), and one-third of one warrant, where each whole warrant entitles the holder to purchase one Ordinary Share (the “Warrant(s)”). The Ordinary Shares and Warrants included in the Units will not trade separately until the 52nd day following the date of the Prospectus (as defined below) (unless the Underwriter informs the Company of its decision to allow earlier separate trading), subject to (a) the Company’s preparation of an audited balance sheet reflecting the receipt by the Company of the proceeds of the Offering (as defined below), (b) the filing of such audited balance sheet with the Securities and Exchange Commission (the “Commission”) on a Current Report on Form 8-K or similar form by the Company that includes such audited balance sheet (the “Closing Form 8-K”), and (c) the Company having issued a press release announcing when such separate trading will begin. No
12,000,000 Units ($10.00 per Unit) UNDERWRITING AGREEMENTUnderwriting Agreement • July 6th, 2021 • JATT Acquisition Corp • Blank checks • New York
12,000,000 Units ($10.00 per Unit) UNDERWRITING AGREEMENTUnderwriting Agreement • June 15th, 2021 • JATT Acquisition Corp • Blank checks • New York
IBERE PHARMACEUTICALS 12,000,000 Units ($10.00 per Unit) UNDERWRITING AGREEMENTUnderwriting Agreement • March 3rd, 2021 • Ibere Pharmaceuticals • Blank checks • New York
10,000,000 Units ($10.00 per Unit) UNDERWRITING AGREEMENTUnderwriting Agreement • February 9th, 2021 • Ibere Pharmaceuticals • Blank checks • New York
